Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 11;2(1):85.
doi: 10.1038/s44276-024-00106-1.

Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis

Rehena Sultana #  1 , Sylvia Chen #  2 , Elaine Hsuen Lim  3 , Rebecca Dent  3 , Balram Chowbay  4   5   6
Affiliations

Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis

Rehena Sultana et al. BJC Rep. .

Abstract

Background: Sacituzumab govitecan (SG) is a promising Trop-2-targeted antibody-drug conjugate (ADC) approved for the treatment of metastatic triple-negative breast cancer (TNBC). Early phase clinical trials have demonstrated good clinical activity and safety profile of SG in various tumor types, albeit with differing response rates and durations. The aim of this systematic review and meta-analysis was to evaluate the clinical efficacy and toxicity of SG and the influence of UGT1A1*28 genotype in clinical trials involving solid tumors.

Methods: A systematic review of the literature from publicly available databases was performed on February 15, 2024 whereby studies published till 15 February 2024 were retrieved according to PRISMA guidelines [PROSPERO #CRD42022359943]. Data extracted included tumor type, sample size, demographic information, SG dose, UGT1A1*28 status, toxicity events, duration of follow-up, response, and survival outcomes. Risks of bias analysis was refereed using the Joanna Briggs Institute quality assessment tool for the cohort and RCT studies using 11 and 13 parameters, respectively. Statistical analysis was performed using the DerSimonian and Laird inverse variance methods. Heterogeneity was assessed using the I2 statistic and Χ2 tests. P value < 0.05 was considered as statistical significance.

Results: Eleven eligible clinical trials comprised of 1578 patients harboring various tumor types including TNBC, lung, genitourinary and gastrointestinal malignancies were included in the systematic review and meta-analysis. Pooled incidences of severe adverse events were minimal at <10%, with the exception of grade 3-4 neutropenia at 37.4%. The median PFS and OS across all studies were 4.9 (95%CI: 4.0-5.8) months and 9.6 (95%CI: 7.6-11.6) months, respectively. Objective response rate across all studies evaluated was 17.1% (95%CI: 12.0-22.1).

Conclusion: Our systematic review and meta-analysis confirmed that SG confers good clinical activity in certain solid tumor types and was tolerable with minimal adverse events. The potential utility of UGT1A1*28 genotyping in predicting clinical response and outcomes could not be determined due to the limited number of studies with available UGT1A1 genotype data.

PubMed Disclaimer

Conflict of interest statement

Competing interests The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA 2020 Flow diagram for systematic reviews.
Fig. 2
Fig. 2. Risk of Bias (RoB) analysis of all selected articles using RoB2 and Newcastle-Ottawa Scale (NOS) tools for randomized controlled trial (RCT) and observational studies respectively.
Risk of Bias of included (a) randomized controlled trials (b) observational studies. Risk of bias summary for all (c) randomized controlled trials (d) observational studies.
Fig. 3
Fig. 3. Forest plot and meta-analysis of grade 3 and 4 toxicities.
Forest plots of (a) grade 3–4 nausea, (b) grade 3–4 vomiting, (c) grade 3–4 diarrhea, (d) grade 3–4 neutropenia, (e) grade 3–4 febrile neutropenia, (f) grade 3–4 fatigue.
Fig. 3
Fig. 3. Forest plot and meta-analysis of grade 3 and 4 toxicities.
Forest plots of (a) grade 3–4 nausea, (b) grade 3–4 vomiting, (c) grade 3–4 diarrhea, (d) grade 3–4 neutropenia, (e) grade 3–4 febrile neutropenia, (f) grade 3–4 fatigue.
Fig. 3
Fig. 3. Forest plot and meta-analysis of grade 3 and 4 toxicities.
Forest plots of (a) grade 3–4 nausea, (b) grade 3–4 vomiting, (c) grade 3–4 diarrhea, (d) grade 3–4 neutropenia, (e) grade 3–4 febrile neutropenia, (f) grade 3–4 fatigue.
Fig. 3
Fig. 3. Forest plot and meta-analysis of grade 3 and 4 toxicities.
Forest plots of (a) grade 3–4 nausea, (b) grade 3–4 vomiting, (c) grade 3–4 diarrhea, (d) grade 3–4 neutropenia, (e) grade 3–4 febrile neutropenia, (f) grade 3–4 fatigue.
Fig. 3
Fig. 3. Forest plot and meta-analysis of grade 3 and 4 toxicities.
Forest plots of (a) grade 3–4 nausea, (b) grade 3–4 vomiting, (c) grade 3–4 diarrhea, (d) grade 3–4 neutropenia, (e) grade 3–4 febrile neutropenia, (f) grade 3–4 fatigue.
Fig. 3
Fig. 3. Forest plot and meta-analysis of grade 3 and 4 toxicities.
Forest plots of (a) grade 3–4 nausea, (b) grade 3–4 vomiting, (c) grade 3–4 diarrhea, (d) grade 3–4 neutropenia, (e) grade 3–4 febrile neutropenia, (f) grade 3–4 fatigue.
Fig. 4
Fig. 4
Forest plot of objective response rates.
Fig. 5
Fig. 5. Forest plot and meta-analysis of survival outcomes.
Forest plots of (a) progression-free survival and (b) overall survival.
Fig. 5
Fig. 5. Forest plot and meta-analysis of survival outcomes.
Forest plots of (a) progression-free survival and (b) overall survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA. 1981;78:5147–50. 10.1073/pnas.78.8.5147 - PMC - PubMed
    1. Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015;21:5131–8. 10.1158/1078-0432.CCR-15-0670 - PubMed
    1. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496–512. 10.18632/oncotarget.4318 - PMC - PubMed
    1. Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ, Vahdat LT, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21:3870–8. 10.1158/1078-0432.CCR-14-3321 - PMC - PubMed
    1. Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, et al. Sacituzumab govitecan, a novel antibody-drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016;14:e75–79. 10.1016/j.clgc.2015.10.002 - PubMed

LinkOut - more resources